Travere Therapeutics (TVTX) News Today $21.01 -0.28 (-1.32%) Closing price 04:00 PM EasternExtended Trading$21.00 -0.01 (-0.02%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Emerald Advisers LLC Acquires 165,085 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Emerald Advisers LLC raised its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,125,744 sharesMarch 24 at 7:08 AM | marketbeat.comSemanteon Capital Management LP Acquires 48,084 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Semanteon Capital Management LP lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 131.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 84,783 shares of the company's stocMarch 22 at 6:04 AM | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 661,603 shares of the company's stock after buying an additioMarch 22 at 3:15 AM | marketbeat.comTravere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGSMarch 17, 2025 | finanznachrichten.deTravere Therapeutics submits sNDA to FDA for approval of FILSPARI in FSGSMarch 17, 2025 | markets.businessinsider.comTravere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGSMarch 17, 2025 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Has $7.43 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Connor Clark & Lunn Investment Management Ltd. cut its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 18.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 426,726 shares of the company's stock after selling 98March 16, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 15, 2025 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and thirteen have assignMarch 15, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading Up 6.7% - Time to Buy?Travere Therapeutics (NASDAQ:TVTX) Shares Up 6.7% - What's Next?March 13, 2025 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 12, 2025 | globenewswire.comUS Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)US Bancorp DE increased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 323.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,795 shares of the company's stock after acqMarch 12, 2025 | marketbeat.comTravere Therapeutics: Tricky Outlook Gives Me Pause For Thought - DowngradeMarch 7, 2025 | seekingalpha.comIeq Capital LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)Ieq Capital LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 20,749 shares of the company's stock, valued at approximately $361,000. OtherFebruary 28, 2025 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for TVTXTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research note issued on Monday, February 24th. Wedbush analyst L. Chico now expects that the company will post earninFebruary 27, 2025 | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) StockJPMorgan Chase & Co. upped their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday.February 26, 2025 | marketbeat.comWedbush Predicts Lower Earnings for Travere TherapeuticsTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Wedbush lowered their Q4 2025 earnings per share estimates for shares of Travere Therapeutics in a research report issued on Monday, February 24th. Wedbush analyst L. Chico now forecasts that the company will earn $0.12 per share for the quFebruary 26, 2025 | marketbeat.comImpax Asset Management Group plc Takes $5.23 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Impax Asset Management Group plc purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 300,000 shares of the company's stock, valued at approximately $5,226,000. ImpaxFebruary 25, 2025 | marketbeat.comTravere Therapeutics to Participate at Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comCitigroup Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00Citigroup lifted their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday.February 24, 2025 | marketbeat.comTravere Therapeutics price target raised to $35 from $31 at CitiFebruary 24, 2025 | markets.businessinsider.comTravere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025February 23, 2025 | insidermonkey.comGuggenheim Keeps Their Buy Rating on Travere Therapeutics (TVTX)February 23, 2025 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Earns "Overweight" Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Travere Therapeutics in a research note on Friday.February 22, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call TranscriptFebruary 22, 2025 | msn.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down After Earnings MissTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down on Disappointing EarningsFebruary 22, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Expectations By $0.15 EPSTravere Therapeutics (NASDAQ:TVTX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%.February 21, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Estimates By $0.15 EPSTravere Therapeutics (NASDAQ:TVTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%.February 21, 2025 | marketbeat.comTravere Therapeutics price target raised to $30 from $24 at TD CowenFebruary 21, 2025 | markets.businessinsider.comTravere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call TranscriptFebruary 21, 2025 | seekingalpha.comTravere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 20, 2025 | globenewswire.comEntropy Technologies LP Purchases New Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,300 shares of the company's stock, valued at appFebruary 15, 2025 | marketbeat.comTravere Therapeutics price target raised to $47 from $45 at GuggenheimFebruary 14, 2025 | markets.businessinsider.comTravere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsFebruary 13, 2025 | globenewswire.comFY2026 Earnings Forecast for TVTX Issued By Leerink PartnrsTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for Travere Therapeutics in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz now expects that the company wiFebruary 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 SharesFebruary 13, 2025 | insidertrades.comTravere Therapeutics (TVTX) to Release Quarterly Earnings on ThursdayTravere Therapeutics (NASDAQ:TVTX) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 SharesTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 3,074 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $76,850.00. Following the completion of the transaction, the insider now directly owns 127,634 shares in the company, valued at approximately $3,190,850. This trade represents a 2.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.February 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote Sells 5,200 SharesTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) SVP William E. Rote sold 5,200 shares of the stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the transaction, the senior vice president now directly owns 98,519 shares of the company's stock, valued at approximately $2,318,152.07. This represents a 5.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.February 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube Sells 11,375 SharesTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric M. Dube sold 11,375 shares of Travere Therapeutics stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the completion of the sale, the chief executive officer now owns 419,173 shares of the company's stock, valued at approximately $10,076,918.92. This trade represents a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.February 13, 2025 | marketbeat.comSandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 54,244 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the sale, the chief accounting officer now directly owns 54,410 shares of the company's stock, valued at approximately $1,360,250. This trade represents a 49.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.February 13, 2025 | marketbeat.comTravere therapeutics CEO Eric M. Dube sells $273,455 in stockFebruary 12, 2025 | msn.comTravere therapeutics officer sells shares worth over $1.35 millionFebruary 12, 2025 | msn.comCanaccord raises Travere Therapeutics target to $45; Keeps BuyFebruary 12, 2025 | msn.comTravere Therapeutics price target raised to $32 from $27 at ScotiabankFebruary 12, 2025 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from ScotiabankFebruary 12, 2025 | markets.businessinsider.comWhy Travere Therapeutics Inc. (TVTX) Went Up On Tuesday?February 12, 2025 | msn.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 12, 2025 | globenewswire.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $32.00Scotiabank increased their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a research report on Wednesday.February 12, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Given New $45.00 Price Target at Evercore ISIEvercore ISI upped their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday.February 12, 2025 | marketbeat.com Remove Ads Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼1.740.68▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼46▲TVTX Articles Average Week Remove Ads Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sarepta Therapeutics News Today Revolution Medicines News Today BridgeBio Pharma News Today Lantheus News Today TG Therapeutics News Today Legend Biotech News Today Axsome Therapeutics News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Blueprint Medicines News Today Krystal Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts